Migraine Survey in Gulf Region

Novartis

Status

Terminated

Conditions

Migraine

Treatments

Other: erenumab

Study type

Observational

Funder types

Industry

Identifiers

NCT06237062

CAMG334AAE02

Details and patient eligibility

About

The objective of this study was to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients who newly started on erenumab over 12 weeks

Full description

This was a longitudinal prospective descriptive primary data collection using a 20 min online survey. Patients were selected by investigators (general neurologists, headache/migraine specialists) in primary care clinics and hospitals. After fulfilling the inclusion criteria, the patient were asked to sign an online informed consent. A 5 min screener followed after which the patient was directed through a link to the full survey. The duration of data collection was for 6 months since the start of survey rolling in each site across centers in the Gulf Region.

Enrollment

37 patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

EM& CM (with or without Medication Overuse Headache (MOH)) patients
Newly Started on erenumab either 70 mg or 140 mg (first dose received within 1 month prior study enrollment and baseline endpoints collection)
Ability to receive 3 monthly doses of erenumab.
Age more than 18 years
Males and Females
Allowing the patients to be stable on 1 adjunctive migraine preventive medication (if present)
Agreed to be included in the study and signed informed consent

Exclusion criteria

Less than 18 years
Age at onset of Migraine more than 50 years
Any contraindications to the start of erenumab as per label
Refusal to sign informed consent
Inability to participate or restricted access to the online survey
Enrolled in an interventional migraine-related study at the time of the study enrollement